Cooperative Agreement U01DA063565
- Federal Cooperative Agreement Award Summary New York University received a $854,818 cooperative agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), with an award date of March 15, 2026 and completion date of December 31, 2030. The project, "Computational Analyses of Family Auditory Communication: Linking Behavior, Vocalization, and Neural Dynamics," will develop machine learning tools and computational methods...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse awarded a Cooperative Agreement totaling $790,937 under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Research Foundation for the State University of New York, effective August 1, 2025, through April 30, 2030. This award supports research investigating the genetic substrates underlying cue-reactivity and cocaine motivation to advance understanding of the biological mechanisms contributing to the...
- Federal Cooperative Agreement Summary Seattle Children's Research Institute received a $944,888 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct deep analysis of transcriptome data to advance understanding of the genetic basis of substance use disorders (SUDs) in rat models. The project, which commenced July 1, 2025 and extends through March 31, 2030, focuses on expanding integrative genome...
- Federal Cooperative Agreement Summary New York University School of Medicine received a $1.75 million Cooperative Agreement from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded July 15, 2025, with completion by June 30, 2027. This award funds a stepped-wedge randomized controlled trial (RCT) designed to evaluate the impact of a technical assistance (TA) intervention on overdose prevention in permanent supportive housing (PSH)...
- Federal Cooperative Agreement Summary Yale University received a $1,636,972 Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded July 15, 2025, with completion targeted for June 30, 2027. The award supports development and validation of the Stimulant Use Disorder Severity Scale (STUDSS) as a Clinical Outcome Assessment (COA) tool qualified by the FDA as a Drug Development Tool (DDT). This initiative...
- Federal Cooperative Agreement Summary The University of California, San Diego received a $4.87 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded July 15, 2025, with a completion date of May 31, 2030. This award funds a prospective binational cohort study examining the intersection between substance use, HIV, and associated comorbidities among people who use drugs (PWUD) in San Diego County,...
- Cooperative Agreement Award Summary The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement totaling $1,799,738 to Lovelace Biomedical Research Institute (awarded September 30, 2025; completion date August 31, 2027) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research applying neuromodulation techniques to enhance the efficacy of motivational interviewing (MI) treatment for substance use disorders (SUDs). The primary research objective involves...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded a Cooperative Agreement totaling $352,064 to The McLean Hospital Corporation (doing business as McLean Hospital) on August 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). This two-year award, with an ultimate completion date of July 31, 2027, supports the development and validation of a novel clinical outcome assessment (COA) measuring substance-related consequences for use in...
- Federal Project Grant Award Summary New York University has been awarded $201,250 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for a two-year project period from June 1, 2025, through May 31, 2027. This Project Grant supports basic neuroscience research investigating the synaptic organization of cholinergic interneurons in the nucleus accumbens, a brain region critical to motivated behaviors and implicated in substance use...
- Federal Cooperative Agreement Summary The National Institutes of Health Office of the Director awarded a $5.0M Cooperative Agreement to New York University School of Medicine under the Trans-NIH Research Support program (CFDA 93.310) on February 16, 2026, with completion scheduled for January 31, 2031. In partnership with SAGE Bionetworks, NYU will establish the NYU-SAGE New Approach Methodologies (NAMS) Data Hub and Coordinating Center (NDHCC) to create an interoperable data ecosystem that...
New York University School of Medicine received a $1.24 million Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 15, 2026, through December 31, 2030. The award supports the development and validation of an integrated system for life-long, high-resolution monitoring of mouse colony life to advance understanding of neurobehavioral mechanisms underlying social behavior and familial structure. The collaborative research initiative brings together behavioral neuroscientists, theoretical researchers, and engineering expertise to leverage recent technological and computational advances—including wireless recording capabilities, cell- and circuit-specific methods for measuring brain activity, neural data analysis algorithms, and multi-animal behavioral interaction quantification—to study neural circuits for social and parental behavior in complex environments. This research addresses fundamental questions about how families adapt to environmental stressors and demonstrates neuroplasticity in the context of survival-critical decision-making. The project capitalizes on recent methodological breakthroughs that now make feasible the longitudinal study of neural and behavioral mechanisms in mammalian family structures under conditions previously impossible to investigate. By establishing this integrated monitoring platform, the work will generate foundational knowledge applicable to understanding social behavior, parental caregiving, and adaptive responses to environmental challenges—research outcomes aligned with NIDA's mission to support basic and translational investigations that advance substance use disorder prevention and treatment through mechanistic understanding of behavior and neurobiology.Federal Cooperative Agreement Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 3/9/26 |